Allogeneic CART progress: platforms, current progress and limitations Article Swipe
Ameneh Shokati
,
Maryam Sanjari-Pour
,
Mahshid Akhavan Rahnama
,
Saghar Hoseinzadeh
,
Mohammad Vaezi
,
Mohammad Ahmadvand
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fimmu.2025.1557157
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fimmu.2025.1557157
Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction methods in process of autologous CAR-T cells). In recent years, the additional editing and non-editing technologies are helping to make allogenic CAR-T therapies a hopeful future treatment. Universal off-the-shelf CAR-T cells can be solved key issues include preventing graft-versus-host disease (GVHD) and time consumption and other challenges faced to allogenic CAR-T cells. Here, we have highlighted the improvement in CAR-T development, particularly in engineering allogenic CAR-T, clinical practices related to these, pre-clinical and clinical studies and their successes which investigated in recent 10 years related to treatment of hematological malignancies and cancers by allogenic CAR-T cells.
Related Topics
Concepts
Chimeric antigen receptor
Medicine
Cart
Immunology
Graft-versus-host disease
Genome editing
Human leukocyte antigen
Disease
Immunotherapy
Immune system
Antigen
Biology
Internal medicine
Gene
CRISPR
Engineering
Biochemistry
Mechanical engineering
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.3389/fimmu.2025.1557157
- https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1557157/pdf
- OA Status
- gold
- Cited By
- 4
- References
- 101
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411253415
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4411253415Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fimmu.2025.1557157Digital Object Identifier
- Title
-
Allogeneic CART progress: platforms, current progress and limitationsWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-06-12Full publication date if available
- Authors
-
Ameneh Shokati, Maryam Sanjari-Pour, Mahshid Akhavan Rahnama, Saghar Hoseinzadeh, Mohammad Vaezi, Mohammad AhmadvandList of authors in order
- Landing page
-
https://doi.org/10.3389/fimmu.2025.1557157Publisher landing page
- PDF URL
-
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1557157/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1557157/pdfDirect OA link when available
- Concepts
-
Chimeric antigen receptor, Medicine, Cart, Immunology, Graft-versus-host disease, Genome editing, Human leukocyte antigen, Disease, Immunotherapy, Immune system, Antigen, Biology, Internal medicine, Gene, CRISPR, Engineering, Biochemistry, Mechanical engineeringTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
4Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 4Per-year citation counts (last 5 years)
- References (count)
-
101Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4411253415 |
|---|---|
| doi | https://doi.org/10.3389/fimmu.2025.1557157 |
| ids.doi | https://doi.org/10.3389/fimmu.2025.1557157 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40574859 |
| ids.openalex | https://openalex.org/W4411253415 |
| fwci | 13.08215637 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000379 |
| mesh[1].descriptor_ui | D016219 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | methods |
| mesh[1].descriptor_name | Immunotherapy, Adoptive |
| mesh[2].qualifier_ui | Q000009 |
| mesh[2].descriptor_ui | D016219 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | adverse effects |
| mesh[2].descriptor_name | Immunotherapy, Adoptive |
| mesh[3].qualifier_ui | Q000639 |
| mesh[3].descriptor_ui | D016219 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | trends |
| mesh[3].descriptor_name | Immunotherapy, Adoptive |
| mesh[4].qualifier_ui | Q000276 |
| mesh[4].descriptor_ui | D000076962 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | immunology |
| mesh[4].descriptor_name | Receptors, Chimeric Antigen |
| mesh[5].qualifier_ui | Q000235 |
| mesh[5].descriptor_ui | D000076962 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | genetics |
| mesh[5].descriptor_name | Receptors, Chimeric Antigen |
| mesh[6].qualifier_ui | Q000378 |
| mesh[6].descriptor_ui | D000076962 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | metabolism |
| mesh[6].descriptor_name | Receptors, Chimeric Antigen |
| mesh[7].qualifier_ui | Q000517 |
| mesh[7].descriptor_ui | D006086 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | prevention & control |
| mesh[7].descriptor_name | Graft vs Host Disease |
| mesh[8].qualifier_ui | Q000276 |
| mesh[8].descriptor_ui | D006086 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | immunology |
| mesh[8].descriptor_name | Graft vs Host Disease |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D000818 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Animals |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D014184 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Transplantation, Homologous |
| mesh[11].qualifier_ui | Q000276 |
| mesh[11].descriptor_ui | D013601 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | immunology |
| mesh[11].descriptor_name | T-Lymphocytes |
| mesh[12].qualifier_ui | Q000637 |
| mesh[12].descriptor_ui | D013601 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | transplantation |
| mesh[12].descriptor_name | T-Lymphocytes |
| mesh[13].qualifier_ui | Q000378 |
| mesh[13].descriptor_ui | D013601 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | metabolism |
| mesh[13].descriptor_name | T-Lymphocytes |
| mesh[14].qualifier_ui | Q000628 |
| mesh[14].descriptor_ui | D019337 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | therapy |
| mesh[14].descriptor_name | Hematologic Neoplasms |
| mesh[15].qualifier_ui | Q000276 |
| mesh[15].descriptor_ui | D019337 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | immunology |
| mesh[15].descriptor_name | Hematologic Neoplasms |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D006801 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Humans |
| mesh[17].qualifier_ui | Q000379 |
| mesh[17].descriptor_ui | D016219 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | methods |
| mesh[17].descriptor_name | Immunotherapy, Adoptive |
| mesh[18].qualifier_ui | Q000009 |
| mesh[18].descriptor_ui | D016219 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | adverse effects |
| mesh[18].descriptor_name | Immunotherapy, Adoptive |
| mesh[19].qualifier_ui | Q000639 |
| mesh[19].descriptor_ui | D016219 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | trends |
| mesh[19].descriptor_name | Immunotherapy, Adoptive |
| mesh[20].qualifier_ui | Q000276 |
| mesh[20].descriptor_ui | D000076962 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | immunology |
| mesh[20].descriptor_name | Receptors, Chimeric Antigen |
| mesh[21].qualifier_ui | Q000235 |
| mesh[21].descriptor_ui | D000076962 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | genetics |
| mesh[21].descriptor_name | Receptors, Chimeric Antigen |
| mesh[22].qualifier_ui | Q000378 |
| mesh[22].descriptor_ui | D000076962 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | metabolism |
| mesh[22].descriptor_name | Receptors, Chimeric Antigen |
| mesh[23].qualifier_ui | Q000517 |
| mesh[23].descriptor_ui | D006086 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | prevention & control |
| mesh[23].descriptor_name | Graft vs Host Disease |
| mesh[24].qualifier_ui | Q000276 |
| mesh[24].descriptor_ui | D006086 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | immunology |
| mesh[24].descriptor_name | Graft vs Host Disease |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D000818 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Animals |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D014184 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Transplantation, Homologous |
| mesh[27].qualifier_ui | Q000276 |
| mesh[27].descriptor_ui | D013601 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | immunology |
| mesh[27].descriptor_name | T-Lymphocytes |
| mesh[28].qualifier_ui | Q000637 |
| mesh[28].descriptor_ui | D013601 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | transplantation |
| mesh[28].descriptor_name | T-Lymphocytes |
| mesh[29].qualifier_ui | Q000378 |
| mesh[29].descriptor_ui | D013601 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | metabolism |
| mesh[29].descriptor_name | T-Lymphocytes |
| mesh[30].qualifier_ui | Q000628 |
| mesh[30].descriptor_ui | D019337 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | therapy |
| mesh[30].descriptor_name | Hematologic Neoplasms |
| mesh[31].qualifier_ui | Q000276 |
| mesh[31].descriptor_ui | D019337 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | immunology |
| mesh[31].descriptor_name | Hematologic Neoplasms |
| type | review |
| title | Allogeneic CART progress: platforms, current progress and limitations |
| biblio.issue | |
| biblio.volume | 16 |
| biblio.last_page | 1557157 |
| biblio.first_page | 1557157 |
| topics[0].id | https://openalex.org/T11491 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | CAR-T cell therapy research |
| topics[1].id | https://openalex.org/T11272 |
| topics[1].field.id | https://openalex.org/fields/22 |
| topics[1].field.display_name | Engineering |
| topics[1].score | 0.9753999710083008 |
| topics[1].domain.id | https://openalex.org/domains/3 |
| topics[1].domain.display_name | Physical Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2204 |
| topics[1].subfield.display_name | Biomedical Engineering |
| topics[1].display_name | Nanowire Synthesis and Applications |
| topics[2].id | https://openalex.org/T10878 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.961899995803833 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | CRISPR and Genetic Engineering |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C3875195 |
| concepts[0].level | 4 |
| concepts[0].score | 0.8619316816329956 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q5099363 |
| concepts[0].display_name | Chimeric antigen receptor |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6208741664886475 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C2777275308 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5109149813652039 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q234668 |
| concepts[2].display_name | Cart |
| concepts[3].id | https://openalex.org/C203014093 |
| concepts[3].level | 1 |
| concepts[3].score | 0.498307466506958 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[3].display_name | Immunology |
| concepts[4].id | https://openalex.org/C2779972918 |
| concepts[4].level | 3 |
| concepts[4].score | 0.46529898047447205 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1194520 |
| concepts[4].display_name | Graft-versus-host disease |
| concepts[5].id | https://openalex.org/C144501496 |
| concepts[5].level | 4 |
| concepts[5].score | 0.45624083280563354 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q5533489 |
| concepts[5].display_name | Genome editing |
| concepts[6].id | https://openalex.org/C188280979 |
| concepts[6].level | 3 |
| concepts[6].score | 0.433973491191864 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q911125 |
| concepts[6].display_name | Human leukocyte antigen |
| concepts[7].id | https://openalex.org/C2779134260 |
| concepts[7].level | 2 |
| concepts[7].score | 0.42423588037490845 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[7].display_name | Disease |
| concepts[8].id | https://openalex.org/C2777701055 |
| concepts[8].level | 3 |
| concepts[8].score | 0.40225085616111755 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[8].display_name | Immunotherapy |
| concepts[9].id | https://openalex.org/C8891405 |
| concepts[9].level | 2 |
| concepts[9].score | 0.3548065423965454 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[9].display_name | Immune system |
| concepts[10].id | https://openalex.org/C147483822 |
| concepts[10].level | 2 |
| concepts[10].score | 0.34368112683296204 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q103537 |
| concepts[10].display_name | Antigen |
| concepts[11].id | https://openalex.org/C86803240 |
| concepts[11].level | 0 |
| concepts[11].score | 0.2171892523765564 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[11].display_name | Biology |
| concepts[12].id | https://openalex.org/C126322002 |
| concepts[12].level | 1 |
| concepts[12].score | 0.15480315685272217 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[12].display_name | Internal medicine |
| concepts[13].id | https://openalex.org/C104317684 |
| concepts[13].level | 2 |
| concepts[13].score | 0.13633200526237488 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[13].display_name | Gene |
| concepts[14].id | https://openalex.org/C98108389 |
| concepts[14].level | 3 |
| concepts[14].score | 0.0770840048789978 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q412563 |
| concepts[14].display_name | CRISPR |
| concepts[15].id | https://openalex.org/C127413603 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q11023 |
| concepts[15].display_name | Engineering |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| concepts[17].id | https://openalex.org/C78519656 |
| concepts[17].level | 1 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q101333 |
| concepts[17].display_name | Mechanical engineering |
| keywords[0].id | https://openalex.org/keywords/chimeric-antigen-receptor |
| keywords[0].score | 0.8619316816329956 |
| keywords[0].display_name | Chimeric antigen receptor |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.6208741664886475 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/cart |
| keywords[2].score | 0.5109149813652039 |
| keywords[2].display_name | Cart |
| keywords[3].id | https://openalex.org/keywords/immunology |
| keywords[3].score | 0.498307466506958 |
| keywords[3].display_name | Immunology |
| keywords[4].id | https://openalex.org/keywords/graft-versus-host-disease |
| keywords[4].score | 0.46529898047447205 |
| keywords[4].display_name | Graft-versus-host disease |
| keywords[5].id | https://openalex.org/keywords/genome-editing |
| keywords[5].score | 0.45624083280563354 |
| keywords[5].display_name | Genome editing |
| keywords[6].id | https://openalex.org/keywords/human-leukocyte-antigen |
| keywords[6].score | 0.433973491191864 |
| keywords[6].display_name | Human leukocyte antigen |
| keywords[7].id | https://openalex.org/keywords/disease |
| keywords[7].score | 0.42423588037490845 |
| keywords[7].display_name | Disease |
| keywords[8].id | https://openalex.org/keywords/immunotherapy |
| keywords[8].score | 0.40225085616111755 |
| keywords[8].display_name | Immunotherapy |
| keywords[9].id | https://openalex.org/keywords/immune-system |
| keywords[9].score | 0.3548065423965454 |
| keywords[9].display_name | Immune system |
| keywords[10].id | https://openalex.org/keywords/antigen |
| keywords[10].score | 0.34368112683296204 |
| keywords[10].display_name | Antigen |
| keywords[11].id | https://openalex.org/keywords/biology |
| keywords[11].score | 0.2171892523765564 |
| keywords[11].display_name | Biology |
| keywords[12].id | https://openalex.org/keywords/internal-medicine |
| keywords[12].score | 0.15480315685272217 |
| keywords[12].display_name | Internal medicine |
| keywords[13].id | https://openalex.org/keywords/gene |
| keywords[13].score | 0.13633200526237488 |
| keywords[13].display_name | Gene |
| keywords[14].id | https://openalex.org/keywords/crispr |
| keywords[14].score | 0.0770840048789978 |
| keywords[14].display_name | CRISPR |
| language | en |
| locations[0].id | doi:10.3389/fimmu.2025.1557157 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2595292759 |
| locations[0].source.issn | 1664-3224 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1664-3224 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Immunology |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_lineage_names | Frontiers Media |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1557157/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Immunology |
| locations[0].landing_page_url | https://doi.org/10.3389/fimmu.2025.1557157 |
| locations[1].id | pmid:40574859 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in immunology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40574859 |
| locations[2].id | pmh:oai:doaj.org/article:8d9160dda20c4be4b8b0f4ce7d5e9a81 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Frontiers in Immunology, Vol 16 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/8d9160dda20c4be4b8b0f4ce7d5e9a81 |
| locations[3].id | pmh:oai:pubmedcentral.nih.gov:12198129 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S2764455111 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | PubMed Central |
| locations[3].source.host_organization | https://openalex.org/I1299303238 |
| locations[3].source.host_organization_name | National Institutes of Health |
| locations[3].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Front Immunol |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12198129 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5068463588 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4197-4325 |
| authorships[0].author.display_name | Ameneh Shokati |
| authorships[0].countries | IR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran |
| authorships[0].institutions[0].id | https://openalex.org/I70640408 |
| authorships[0].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[0].institutions[0].country_code | IR |
| authorships[0].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ameneh Shokati |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran |
| authorships[1].author.id | https://openalex.org/A5118135916 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Maryam Sanjari-Pour |
| authorships[1].countries | IR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1516879 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Clinical Biochemistry, Faculty of Medical Science, Tarbiat Modarres University, Tehran, Iran |
| authorships[1].institutions[0].id | https://openalex.org/I1516879 |
| authorships[1].institutions[0].ror | https://ror.org/03mwgfy56 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I1516879 |
| authorships[1].institutions[0].country_code | IR |
| authorships[1].institutions[0].display_name | Tarbiat Modares University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Maryam Sanjari-Pour |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Clinical Biochemistry, Faculty of Medical Science, Tarbiat Modarres University, Tehran, Iran |
| authorships[2].author.id | https://openalex.org/A5049043379 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-8226-3290 |
| authorships[2].author.display_name | Mahshid Akhavan Rahnama |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[2].affiliations[0].raw_affiliation_string | Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran |
| authorships[2].institutions[0].id | https://openalex.org/I70640408 |
| authorships[2].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Mahshid Akhavan Rahnama |
| authorships[2].is_corresponding | True |
| authorships[2].raw_affiliation_strings | Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran |
| authorships[3].author.id | https://openalex.org/A5118135917 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Saghar Hoseinzadeh |
| authorships[3].countries | IR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I163205636 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran |
| authorships[3].institutions[0].id | https://openalex.org/I163205636 |
| authorships[3].institutions[0].ror | https://ror.org/04krpx645 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I163205636 |
| authorships[3].institutions[0].country_code | IR |
| authorships[3].institutions[0].display_name | Tabriz University of Medical Sciences |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Saghar Hoseinzadeh |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran |
| authorships[4].author.id | https://openalex.org/A5101952114 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3186-5491 |
| authorships[4].author.display_name | Mohammad Vaezi |
| authorships[4].countries | IR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[4].affiliations[0].raw_affiliation_string | Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran |
| authorships[4].institutions[0].id | https://openalex.org/I70640408 |
| authorships[4].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[4].institutions[0].country_code | IR |
| authorships[4].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mohammad Vaezi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran |
| authorships[5].author.id | https://openalex.org/A5059798775 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Mohammad Ahmadvand |
| authorships[5].countries | IR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[5].affiliations[0].raw_affiliation_string | Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran |
| authorships[5].institutions[0].id | https://openalex.org/I70640408 |
| authorships[5].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[5].institutions[0].country_code | IR |
| authorships[5].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Mohammad Ahmadvand |
| authorships[5].is_corresponding | True |
| authorships[5].raw_affiliation_strings | Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1557157/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Allogeneic CART progress: platforms, current progress and limitations |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11491 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | CAR-T cell therapy research |
| related_works | https://openalex.org/W4400093351, https://openalex.org/W3193909393, https://openalex.org/W2322350723, https://openalex.org/W2618011907, https://openalex.org/W4226229889, https://openalex.org/W2945144341, https://openalex.org/W2929722753, https://openalex.org/W4229981964, https://openalex.org/W2974098477, https://openalex.org/W3126687991 |
| cited_by_count | 4 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 4 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fimmu.2025.1557157 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2595292759 |
| best_oa_location.source.issn | 1664-3224 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1664-3224 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Immunology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_lineage_names | Frontiers Media |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1557157/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Immunology |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fimmu.2025.1557157 |
| primary_location.id | doi:10.3389/fimmu.2025.1557157 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2595292759 |
| primary_location.source.issn | 1664-3224 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1664-3224 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Immunology |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_lineage_names | Frontiers Media |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1557157/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Immunology |
| primary_location.landing_page_url | https://doi.org/10.3389/fimmu.2025.1557157 |
| publication_date | 2025-06-12 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4390909128, https://openalex.org/W4400947310, https://openalex.org/W4220859730, https://openalex.org/W3176970621, https://openalex.org/W3148729173, https://openalex.org/W4403682533, https://openalex.org/W4404024270, https://openalex.org/W3006138994, https://openalex.org/W6859315200, https://openalex.org/W3120017373, https://openalex.org/W2998345757, https://openalex.org/W4386029184, https://openalex.org/W4239798175, https://openalex.org/W576867606, https://openalex.org/W4399525128, https://openalex.org/W4400474295, https://openalex.org/W4399386014, https://openalex.org/W4401002391, https://openalex.org/W4386091635, https://openalex.org/W4406305378, https://openalex.org/W6768963086, https://openalex.org/W4404476926, https://openalex.org/W3172565803, https://openalex.org/W6875030617, https://openalex.org/W6861652179, https://openalex.org/W4392921484, https://openalex.org/W4404064387, https://openalex.org/W6687639916, https://openalex.org/W4386790994, https://openalex.org/W2324071661, https://openalex.org/W2793887515, https://openalex.org/W1561756904, https://openalex.org/W6863410662, https://openalex.org/W4401372023, https://openalex.org/W2957861560, https://openalex.org/W4376615273, https://openalex.org/W3135011427, https://openalex.org/W2773804840, https://openalex.org/W3014583893, https://openalex.org/W3082855561, https://openalex.org/W3133229959, https://openalex.org/W3176532045, https://openalex.org/W2903062212, https://openalex.org/W4200248834, https://openalex.org/W3169193862, https://openalex.org/W4283023614, https://openalex.org/W4200626931, https://openalex.org/W4200201081, https://openalex.org/W2583070206, https://openalex.org/W4304807853, https://openalex.org/W4231056610, https://openalex.org/W2759643796, https://openalex.org/W4310104199, https://openalex.org/W2591433826, https://openalex.org/W4304112200, https://openalex.org/W3113171896, https://openalex.org/W4317802192, https://openalex.org/W4318071619, https://openalex.org/W4297020650, https://openalex.org/W2077659966, https://openalex.org/W2757102439, https://openalex.org/W2067129056, https://openalex.org/W3206838739, https://openalex.org/W4404395078, https://openalex.org/W2765978780, https://openalex.org/W2137409670, https://openalex.org/W2762787825, https://openalex.org/W1839053269, https://openalex.org/W2001962483, https://openalex.org/W4307309183, https://openalex.org/W2897295193, https://openalex.org/W4386637223, https://openalex.org/W2893585523, https://openalex.org/W3121261287, https://openalex.org/W4388048240, https://openalex.org/W4283327537, https://openalex.org/W2089084676, https://openalex.org/W2034184344, https://openalex.org/W2289449831, https://openalex.org/W4390826709, https://openalex.org/W3213904764, https://openalex.org/W3212699181, https://openalex.org/W4365514164, https://openalex.org/W4385702617, https://openalex.org/W4310112833, https://openalex.org/W4310161875, https://openalex.org/W4308399396, https://openalex.org/W4283720903, https://openalex.org/W3132062361, https://openalex.org/W4389231419, https://openalex.org/W4310924652, https://openalex.org/W3032334108, https://openalex.org/W3212431903, https://openalex.org/W4310106398, https://openalex.org/W2936355201, https://openalex.org/W2548694234, https://openalex.org/W2794149319, https://openalex.org/W4308434465, https://openalex.org/W4394060769, https://openalex.org/W2211296957, https://openalex.org/W4200368038 |
| referenced_works_count | 101 |
| abstract_inverted_index.T | 4, 12 |
| abstract_inverted_index.a | 21, 64 |
| abstract_inverted_index.10 | 123 |
| abstract_inverted_index.In | 48 |
| abstract_inverted_index.as | 16 |
| abstract_inverted_index.be | 32, 73 |
| abstract_inverted_index.by | 133 |
| abstract_inverted_index.in | 42, 99, 103, 121 |
| abstract_inverted_index.of | 44, 128 |
| abstract_inverted_index.to | 10, 31, 59, 89, 110, 126 |
| abstract_inverted_index.we | 94 |
| abstract_inverted_index.(if | 25 |
| abstract_inverted_index.and | 27, 34, 54, 82, 85, 113, 116, 131 |
| abstract_inverted_index.are | 30, 57 |
| abstract_inverted_index.can | 72 |
| abstract_inverted_index.for | 19 |
| abstract_inverted_index.key | 75 |
| abstract_inverted_index.the | 51, 97 |
| abstract_inverted_index.also | 35 |
| abstract_inverted_index.cell | 13 |
| abstract_inverted_index.have | 7, 95 |
| abstract_inverted_index.make | 60 |
| abstract_inverted_index.such | 15 |
| abstract_inverted_index.time | 83 |
| abstract_inverted_index.with | 39 |
| abstract_inverted_index.CAR-T | 46, 62, 70, 91, 100, 135 |
| abstract_inverted_index.Here, | 93 |
| abstract_inverted_index.cells | 6, 18, 71 |
| abstract_inverted_index.donor | 24 |
| abstract_inverted_index.faced | 88 |
| abstract_inverted_index.lower | 36 |
| abstract_inverted_index.other | 86 |
| abstract_inverted_index.risks | 37 |
| abstract_inverted_index.their | 117 |
| abstract_inverted_index.which | 119 |
| abstract_inverted_index.years | 124 |
| abstract_inverted_index.(GVHD) | 81 |
| abstract_inverted_index.CAR-T, | 106 |
| abstract_inverted_index.cells. | 92, 136 |
| abstract_inverted_index.future | 66 |
| abstract_inverted_index.issues | 76 |
| abstract_inverted_index.recent | 49, 122 |
| abstract_inverted_index.solved | 74 |
| abstract_inverted_index.these, | 111 |
| abstract_inverted_index.years, | 50 |
| abstract_inverted_index.(CAR-T) | 5 |
| abstract_inverted_index.antigen | 2 |
| abstract_inverted_index.avoided | 33 |
| abstract_inverted_index.cancers | 132 |
| abstract_inverted_index.cells). | 47 |
| abstract_inverted_index.disease | 80 |
| abstract_inverted_index.editing | 53 |
| abstract_inverted_index.effects | 29 |
| abstract_inverted_index.helping | 58 |
| abstract_inverted_index.hopeful | 65 |
| abstract_inverted_index.include | 77 |
| abstract_inverted_index.methods | 41 |
| abstract_inverted_index.process | 43 |
| abstract_inverted_index.related | 109, 125 |
| abstract_inverted_index.studies | 115 |
| abstract_inverted_index.chimeric | 1 |
| abstract_inverted_index.clinical | 107, 114 |
| abstract_inverted_index.compared | 9 |
| abstract_inverted_index.receptor | 3 |
| abstract_inverted_index.suitable | 22 |
| abstract_inverted_index.Allogenic | 0 |
| abstract_inverted_index.Universal | 68 |
| abstract_inverted_index.allogenic | 61, 90, 105, 134 |
| abstract_inverted_index.practices | 108 |
| abstract_inverted_index.rejection | 28 |
| abstract_inverted_index.successes | 118 |
| abstract_inverted_index.therapies | 14, 63 |
| abstract_inverted_index.treatment | 127 |
| abstract_inverted_index.additional | 52 |
| abstract_inverted_index.advantages | 8 |
| abstract_inverted_index.associated | 38 |
| abstract_inverted_index.autologous | 11, 45 |
| abstract_inverted_index.challenges | 87 |
| abstract_inverted_index.preventing | 78 |
| abstract_inverted_index.treatment. | 67 |
| abstract_inverted_index.HLA-matched | 23 |
| abstract_inverted_index.consumption | 84 |
| abstract_inverted_index.engineering | 104 |
| abstract_inverted_index.highlighted | 96 |
| abstract_inverted_index.improvement | 98 |
| abstract_inverted_index.non-editing | 55 |
| abstract_inverted_index.production, | 20 |
| abstract_inverted_index.availability | 17 |
| abstract_inverted_index.development, | 101 |
| abstract_inverted_index.investigated | 120 |
| abstract_inverted_index.malignancies | 130 |
| abstract_inverted_index.particularly | 102 |
| abstract_inverted_index.pre-clinical | 112 |
| abstract_inverted_index.technologies | 56 |
| abstract_inverted_index.transduction | 40 |
| abstract_inverted_index.hematological | 129 |
| abstract_inverted_index.off-the-shelf | 69 |
| abstract_inverted_index.graft-versus-host | 79 |
| abstract_inverted_index.graft-vs-host-disease | 26 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5059798775, https://openalex.org/A5049043379 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| corresponding_institution_ids | https://openalex.org/I70640408 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7599999904632568 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.97236566 |
| citation_normalized_percentile.is_in_top_1_percent | True |
| citation_normalized_percentile.is_in_top_10_percent | True |